Rosetta Genomics Names Genekor S.A Exclusive Distributor for Three microRNA-based Assays in Greece
REHOVOT, Israel & PHILADELPHIA & ATHENS, Greece—-Rosetta Genomics, Ltd. , a leading developer of microRNA-based molecular diagnostics, and Genekor S.A, a leading molecular diagnostic service provider in Greece, announced today the signing of an exclusive distribution agreement for three of Rosetta Genomics’ diagnostic tests in Greece.
Researchers recently uncovered the potential of a cholesterol drug, introduced in the 1980s, that may offer mesothelioma victims an effective treatment for the deadly and incurable cancer. The drug, Lovastatin, is used to treat and control high levels of cholesterol among patients.
Early on, scientists found that in initial studies of the drug, dating back 20 years, it had an unexpected and very powerful effect on killing cancerous cells within humans. At that time, however, the anti-cancer effect was considered too risky to continue studying because of the extremely high doses that were needed to be given to a cancer patient. Researchers put the study on hold, according to news reports, until recently when scientists at a Nashville, Tenn., clinic started providing the drug to pleural mesothelioma patients.
Details of Lovastatin and its Cancer-Killing Potential
Researchers have given little notice to Lovastatin as a treatment for mesothelioma cancer even though a stage-four melanoma patient had received treatments of Lovastatin in 2000 and currently remains cancer-free, nearly nine years later. While researchers are unsure that they can find the same success of the melanoma patient, the use of Lovastatin may potentially reduce or slow the cancerous production of mesothelioma cells, which can kill an individual within as little as one year after symptoms appear.
A study published in the American Journal of Respiratory and Critical Care Medicine found that the cholesterol drug induces apoptosis on mesothelioma cells. Apoptosis is also described as programmed cell death, according to the Reproductive and Cardiovascular Disease Research Group. Apoptosis occurs when a stimuli is introduced to a variety of cells in which the cells begin to commit cell suicide. The study looked at the morophologic changes, histologic evidence of nuclear condensation and degeneration, and flow-cytometric analysis of DNA content of the mesothelioma cancer cells treated with Lovastatin and determined it a potentially sufficient treatment for mesothelioma.
What is Lovastatin?
Lovastatin is part of a group of drugs known as HMG-CoA reductase inhibitors (statins). The drugs decrease the production of bad cholesterol within the body. It is often prescribed to patients as an oral pill that is taken in low-doses — once every four weeks.
Lovastatin does have reported side effects, which have not been fully studied on mesothelioma patients, however, according to the National Library of Medicine (NLM) the side effects include:
* hives, rashes and itching
* loss of appetite
* flu-like symptoms
* nausea as well as pain in upper right part of stomach
* extreme tiredness
* yellowing of skin and eyes
* lack of energy
* difficulty breathing and swallowing
* swelling of face, throat, tongue, lips, eyes, hands, feet, ankles and
* lower legs/calf muscles
* muscle pain, tenderness or weakness
* fever
* unusual bleeding or bruising
* hoarseness
* constipation
What to do If Diagnosed With Mesothelioma
Mesothelioma cancer has become increasingly prevalent in the United States and around the world. Individuals who were exposed to a mineral known as vermiculite containing deadly asbestos may have had the condition for 20 or more years without any signs of the cancer within their bodies.
Once researchers began discovering the link between asbestos exposure and mesothelioma, asbestos was banned in the United States and around the world. However, shipments of asbestos are still being imported into the United States and millions of Americans remain at risk for exposure because of the prevalence of asbestos in many homes, apartments, schools, universities, hospitals and government buildings.
Those who have suffered from mesothelioma cancer or feel they may have been a victim of asbestos exposure have the ability to consult a legal professional for a potential mesothelioma lawsuit. Such litigation may appear overwhelming to a victim, but can potentially offer monetary compensation for the heavy expenses associated with receiving mesothelioma medical treatments. Consulting a mesothelioma attorney is often a free legal service and may add peace of mind for mesothelioma victims, their families and friends.
About the Author
Learn more about mesothelioma and other various treatments at http://mesothelioma.legalview.com/ . Also, visit the LegalView homepage (http://www.LegalView.com) and learn about the Levaquin side effects or the Digitek digoxin recall.
Press Release
Rosetta Genomics Ltd. Posted on:29 Jul 10 Rosetta Genomics, Ltd. (NASDQ:ROSG), a leading developer of microRNA-based molecular diagnostics, and Genekor S.A, a leading molecular diagnostic service provider in Greece, announced today the signing of an exclusive distribution agreement for three of Rosetta Genomics’ diagnostic tests in Greece.
What is the Government doing about mesothelioma?
Mesothelioma is one of the biggest killers in the UK, and statistics are set to peak over the next 10 to 15 years as the disease has a long incubation period. Swept under the carpet for years, the problem of the ‘Silent Killer’ (as the disease has become known) has recently received much higher public exposure with the successful conclusion of a court case centred on which insurance policy providers were liable to pay out in the event of a victim developing the disease – the insurers covering the company at the time of exposure or the insurers involved at the time of diagnosis. The ‘trigger case’ lasted for nine weeks in 2008, and was regarded by specialist lawyers (solicitors) representing the families of mesothelioma victims as a landmark in how the courts would regard claims brought against former employers for injuries or illness as a direct result of exposure to asbestos.
The profile for this preventable industrial disease has been raised further by the decision to make February 27th 2008 as Action Mesothelioma Day. The day was marked by events throughout the UK with the purpose of raising awareness in the media and with the public of the disease. An international conference discussed advances in the treatment of mesothelioma. John Edwards, Consultant Thoracic Surgeon and chair of the British Mesothelioma Interest Group, who addressed the conference said: “Researchers are desperate for funds to develop life saving treatments. Mesothelioma is far and away the least researched of the top twenty cancers in the UK. Funding for a UK National Centre for Asbestos Related Diseases is a priority. Such a virtual institution would encourage collaboration and stimulate research to generate future treatments to prolong and save lives.”
The Government has recognized that the ongoing problem of mesothelioma is one that has not subsided over time. Although the use of asbestos as a building material has been banned for over 20 years, there are still thousands of public buildings – in particular schools – that still have asbestos as part of their main structures. Although the asbestos has been coated with a protective layer of silicon to prevent dust escaping into the atmosphere, any damage to this layer could result in deadly dust being released. Those involved in the ongoing battle against the disease also fear that plumbers, electricians and other maintenance workers are at risk from exposure as they work on older properties that still contain asbestos.
Unite and other trade unions, health professionals, mesothelioma patients’ asbestos support groups and Michael Clapham MP, chair All Party Asbestos sub committee, are leading the proposal for the National Centre for Asbestos Related Diseases. The development group has wide support and has met the Prime Minister’s special advisor on health in Downing Street, the national director for cancer and the minister for health with responsibility for cancer. The meeting was seen as a step forward by all parties indicating that the government takes the problem of mesothelioma seriously. The campaign is calling on the government to provide funding for a National Centre for Asbestos Related Disease to keep the UK in line with other western countries. The Australian government has already provided $6.2 million to fund a National Centre for Asbestos Related Disease. British sufferers and support groups are asking the government to match this funding , around £5 to 10 million, to provide a similar centre in the UK.
As the profile of this industrial disease is raised, the hope amongst specialist solicitors representing families of the victims of mesothelioma is that the long battle for compensation that many families face will become easier, ensuring that victims receive the compensation they deserve.
About the Author
http://www.1stclaims.co.uk is run by a non-practising Personal Injury Solicitor with over 14 years personal injury claims experience.We deal in a range of claims, including personal injury claims and compensation. Please visit http://www.1stclaims.co.uk for further information.
Continued research regarding mesothelioma and the link to asbestos exposure is necessary if we ever hope to find a cure. Imagine someone you love returning home from the second world war. They find a job as an auto mechanic, raise a family, and play by the rules. Decades later, they tragically die from mesothelioma cancer because someone failed to warn them of the dangers of asbestos fibers. Does any reasonable person believe this is fair or just? Of course not. Unfortunately, we cannot go back in time and prevent the asbestos exposure. But what we can do is try to promote public awareness about this deadly disease and highlight some of the great research being done.
One interesting study is called, “Malignant mesothelioma: attributable risk of asbestos exposure.” By R Spirtas, E F Heineman, L Bernstein, G W Beebe, R J Keehn, A Stark, B L Harlow, and J Benichou – Occup Environ Med 1994;51:804-811 doi:10.1136/oem.51.12.804. Here is an excerpt:
“OBJECTIVES–To evaluate a case-control study of malignant mesothelioma through patterns of exposure to asbestos based upon information from telephone interviews with next of kin. METHODS–Potential cases, identified from medical files and death certificates, included all people diagnosed with malignant mesothelioma and registered during 1975-1980 by the Los Angeles County Cancer Surveillance Program, the New York State Cancer Registry (excluding New York City), and 39 large Veterans Administration hospitals. Cases whose diagnosis was confirmed in a special pathology review as definite or probable mesothelioma (n = 208) were included in the analysis. Controls (n = 533) had died of other causes, excluding cancer, respiratory disease, suicide, or violence. Direct exposure to asbestos was determined from responses to three types of questions: specific queries as to any exposure to asbestos; occupational or non-vocational participation in any of nine specific activities thought to entail exposure to asbestos; and analysis of life-time work histories. Indirect exposures were assessed through residential histories and reported contact with family members exposed to asbestos. RESULTS–Among men with pleural mesothelioma the attributable risk (AR) for exposure to asbestos was 88% (95% confidence interval (95% CI) 76-95%). For men, the AR of peritoneal cancer was 58% (95% CI 20-89%). For women (both sites combined), the AR was 23% (95% CI 3-72%). The large differences in AR by sex are compatible with the explanations: a lower background incidence rate in women, lower exposure to asbestos, and greater misclassification among women. CONCLUSIONS–Most of the pleural and peritoneal mesotheliomas in the men studied were attributable to exposure to asbestos. The situation in women was less definitive.”
Another good study is called, “Chrysotile asbestos is the main cause of pleural mesothelioma” by Allan H. Smith, MD, PhD, Catherine C. Wright, MPH
School of Public Health, University of California, Berkeley, CA. Here is an excerpt:
“Abstract – In contrast to amphibole forms of asbestos, chrysotile asbestos is often claimed to be only a minor cause of malignant pleural mesothelioma, a highly fatal cancer of the lining of the thoracic cavity. In this article we examine the evidence from animal and human studies that relates to this issue. Reported data do not support widely quoted views regarding the relative inertness of chrysotile fibers in mesothelioma causation. In fact, examination of all pertinent studies makes it clear that chrysotile asbestos is similar in potency to amphibole asbestos. Since asbestos is the major cause of mesothelioma, and chrysotile constitutes 95% of all asbestos use world wide, it can be concluded that chrysotile asbestos is the main cause of pleural mesothelioma in humans.”
If you found either of these excerpts interesting, I would urge you to read the studies in their entirety. We all owe a debt of gratitude to these researchers, and should do our best to promote public awareness. This article should not be construed as legal or medical advice.”
About the Author
Monty Wrobleski is the author of this article on asbestos attorney, asbestos lawyer